Journal: Pharmaceutical Biology

Article Title: Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels

doi: 10.1080/13880209.2023.2184481

Figure Lengend Snippet: The effects of TMYX on the HIF-1α signaling pathway in NR rats. (A) Effect of TMYX on the expression of the GPER gene and protein in the myocardial HIF-1α pathway of NR rats. (B) Effect of TMYX on the expression of the ERK gene and p-ERK protein in the myocardial HIF-1α pathway of NR rats. (C) Effect of TMYX on the expression of the HIF-1α gene and protein in the myocardial HIF-1α pathway of NR rats. The data are expressed as the mean ± SD; n = 3 animals/group; * p < 0.05, ** p < 0.01, *** p < 0.001 vs. Sham group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. NR group.

Article Snippet: In order to observe whether TMYX can alleviate NR by activating GPER to regulate the HIF-1α pathway and downstream potassium channel, a GPER blocker (G-15, Batch No. 1161002-05-6, MCE, China), PKA blocker (H-89, Batch No. B 1427, Sigma, USA), eNOS blocker (L-NAME, Batch No. N 5751, Sigma, USA), sGC inhibitor (ODQ, Batch No. O 3636, Sigma, USA), and four K + channel (calcium-activated potassium channel, ATP-sensitive potassium channel, inward rectifier potassium channel, and voltage-dependent potassium channel) inhibitors (TEA: Batch No. T2265-25G, Gli: Batch No. G0639-5G-9, Bacl 2 : Batch No. 202738-5 G, 4-AP: Batch No. 275875-1 G, Sigma, USA) were administered to the isolated coronary microvasculature.

Techniques: Expressing

Journal: Pharmaceutical Biology

Article Title: Tongmai Yangxin pill alleviates myocardial no-reflow by activating GPER to regulate HIF-1α signaling and downstream potassium channels

doi: 10.1080/13880209.2023.2184481

Figure Lengend Snippet: Effect of TMYX on the diastolic function of isolated coronary microvasculature by the HIF-1α pathway. (A) Effect of GPER inhibitor on the diastolic function of isolated coronary microvasculature of TMYX. (B) Effect of PKA inhibitor on the diastolic function of isolated coronary microvasculature of TMYX. (C) Effect of eNOS inhibitor on the diastolic function of isolated coronary microvascular of TMYX. (D) Effect of sGC inhibitor on the diastolic function of isolated coronary microvasculature of TMYX. (E–H) Effect of four K + channel inhibitors on the diastolic function of isolated coronary microvascular of TMYX. The data are expressed as the mean ± SD; n = 3 animals/group; ** p < 0.01, *** p < 0.001 vs. DMSO group; # p < 0.05, ## p < 0.01, ### p < 0.001 vs. TMYX group.

Article Snippet: In order to observe whether TMYX can alleviate NR by activating GPER to regulate the HIF-1α pathway and downstream potassium channel, a GPER blocker (G-15, Batch No. 1161002-05-6, MCE, China), PKA blocker (H-89, Batch No. B 1427, Sigma, USA), eNOS blocker (L-NAME, Batch No. N 5751, Sigma, USA), sGC inhibitor (ODQ, Batch No. O 3636, Sigma, USA), and four K + channel (calcium-activated potassium channel, ATP-sensitive potassium channel, inward rectifier potassium channel, and voltage-dependent potassium channel) inhibitors (TEA: Batch No. T2265-25G, Gli: Batch No. G0639-5G-9, Bacl 2 : Batch No. 202738-5 G, 4-AP: Batch No. 275875-1 G, Sigma, USA) were administered to the isolated coronary microvasculature.

Techniques: Isolation